NSE: LUPIN | BSE: 500257

Falling Comet

Download real time

1978.90 10.20 (0.52%)

32.52% Gain from 52W Low

596.4K NSE+BSE Volume

NSE 23 May, 2025 3:31 PM (IST)

90,359.8

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Search Inside the pdf :

Lupin Ltd.

15 May 2025

1978.90

0.52%

Niche products and superior execution lead to robust 4Q and FY25 performance

Neutral: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) delivered slightly better-than-expected revenue, EBITDA, and PAT for the quarter (4% beat). LPC continues to track well in the US generics segment (40% of 4Q sales), clocking the highest quarterly run-rate of USD245m over the past 24 quarters.

Motilal Oswal increased Neutral price target of Lupin Ltd. to 2200.0 on 15 May, 2025.

Lupin Ltd.

13 Mar 2025

1978.90

0.52%

LUPIN LIMITED

Hold: Lupin Ltd.

Target

Geojit BNP Paribas

Lupin Ltd. has an average target of 2346.11 from 9 brokers.

Lupin Ltd.

13 Feb 2025

1978.90

0.52%

LUPIN LTD

Buy: Lupin Ltd.

Recommendation Target

Prabhudas Lilladhar

Motilal Oswal increased Neutral price target of Lupin Ltd. to 2200.0 on 15 May, 2025.

Lupin Ltd.

13 Feb 2025

1978.90

0.52%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock.

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

13 Feb 2025

1978.90

0.52%

Strong pipeline to support growth in the US and India

Buy: Lupin Ltd.

KRChoksey

Lupin’s revenue beat our estimates (+3.1%) due to better-than-expected revenue in North America and India. EBITDA beat our estimates due to better-than-expected gross profit and lower-than-expected other expenses. Adj. PAT beat our estimates due to lower-than-expected depreciation expense.

Lupin Ltd. has an average target of 2346.11 from 9 brokers.

Lupin Ltd.

13 Feb 2025

1978.90

0.52%

Lupin (BUY): High-margin US region to have growth visibility till FY27

Buy: Lupin Ltd.

Target

BOB Capital Markets Ltd.

US sales cc quarterly run rate at its highest-ever level of US$ 235mn, expect to inch up to US$ 250mn in FY26E and US$ 280mn in FY27E

Motilal Oswal increased Neutral price target of Lupin Ltd. to 2200.0 on 15 May, 2025.

Lupin Ltd.

30 Dec 2024

1978.90

0.52%

Delay in approval for Amneal's gProAir an unexpected positive

Buy: Lupin Ltd.

Emkay

In Teva’s litigation with Amneal which blocked Amneal’s launch of gProAir, the US Court of Appeals had recently asked Teva to delist its patents in contention. While the ruling was expected to clear the way for Amneal’s launch of gProAir, Teva has now filed a petition seeking an en banc rehearing.

Lupin Ltd. has an average target of 2346.11 from 9 brokers.

Lupin Ltd.

16 Dec 2024

1978.90

0.52%

Lupin (BUY): Reduction in in-licence portfolio to increase margins

Buy: Lupin Ltd.

BOB Capital Markets Ltd.

LPC's domestic region in-licence portfolio fell from 15% in Q2FY24 to 12% in Q2FY25 and is expected to reduce further to ~10% by FY26

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

12 Nov 2024

1978.90

0.52%

Focus on complex portfolio to drive growth

Buy: Lupin Ltd.

Target

KRChoksey

Lupin’s revenue was largely in-line with our estimates (+2.3%). EBITDA and Adj. PAT beat our estimates significantly due to lower-than-expected COGS and lower than expected other expenses.
We increase our FY2E6 EPS estimates to INR 79.7 (previously: 78.8) as we anticipate expanding respiratory portfolio in Europe, upcoming injectable launches include glucagon and dalbavancin, and GLP-1 launch in India in 2026E will drive growth.